CD19 and acute lymphoblastic leukemia: Anti-CD19/CD3 bi-specific T-cell-mAb, which binds simultaneously to CD3-positive cytotoxic T cells and to CD19-positive B cells; endogenous T cells recognize and eliminate CD19-positive ALL blasts